celecoxib has been researched along with Cognition Disorders in 11 studies
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We used data from the Alzheimer's Disease Anti-Inflammatory Prevention Trial to compare performance of a four-test Telephone Assessment Battery (TAB) that included the Telephone Interview for Cognitive Status (TICS) to that of a traditional in-person Cognitive Assessment Battery." | 2.78 | Screening by telephone in the Alzheimer's disease anti-inflammatory prevention trial. ( Brandt, J; Breitner, JC; Luis, CA; Martin, B; Reckess, GZ; Zandi, P, 2013) |
| "Celecoxib 200 mg bid did not slow the progression of AD in this study, and the occurrence of adverse events was as expected for an elderly population with a complex chronic medical condition." | 2.73 | Long-term efficacy and safety of celecoxib in Alzheimer's disease. ( Niculescu, L; Robbins, J; Soininen, H; West, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zolotovskaia, IA | 1 |
| Davydkin, IL | 1 |
| Reckess, GZ | 1 |
| Brandt, J | 2 |
| Luis, CA | 1 |
| Zandi, P | 1 |
| Martin, B | 1 |
| Breitner, JC | 3 |
| Tang, J | 1 |
| Xiao, W | 1 |
| Li, Q | 1 |
| Deng, Q | 1 |
| Chu, X | 1 |
| Chen, Y | 1 |
| Pan, D | 1 |
| Fu, J | 1 |
| Small, GW | 1 |
| Siddarth, P | 1 |
| Silverman, DH | 1 |
| Ercoli, LM | 1 |
| Miller, KJ | 1 |
| Lavretsky, H | 1 |
| Bookheimer, SY | 1 |
| Huang, SC | 1 |
| Barrio, JR | 1 |
| Phelps, ME | 1 |
| Meinert, CL | 1 |
| McCaffrey, LD | 1 |
| Borre, Y | 1 |
| Lemstra, S | 1 |
| Westphal, KG | 1 |
| Morgan, ME | 1 |
| Olivier, B | 1 |
| Oosting, RS | 1 |
| Casolini, P | 1 |
| Catalani, A | 1 |
| Zuena, AR | 1 |
| Angelucci, L | 1 |
| Melnikova, T | 1 |
| Savonenko, A | 1 |
| Wang, Q | 1 |
| Liang, X | 1 |
| Hand, T | 1 |
| Wu, L | 1 |
| Kaufmann, WE | 1 |
| Vehmas, A | 1 |
| Andreasson, KI | 1 |
| Soininen, H | 1 |
| West, C | 1 |
| Robbins, J | 1 |
| Niculescu, L | 1 |
| Martin, BK | 1 |
| Szekely, C | 1 |
| Piantadosi, S | 1 |
| Craft, S | 1 |
| Evans, D | 1 |
| Green, R | 1 |
| Mullan, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)[NCT00007189] | Phase 3 | 2,625 participants | Interventional | 2001-01-31 | Completed | ||
| Alzheimer's Disease Anti-Inflammatory Prevention Trial Follow-Up Study[NCT01417130] | 1,650 participants (Anticipated) | Observational | 2009-08-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for celecoxib and Cognition Disorders
| Article | Year |
|---|---|
Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents; Celecoxib; Cognit | 2013 |
Screening by telephone in the Alzheimer's disease anti-inflammatory prevention trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Celecoxib; Cognition Disorders; Female; Geriatric Assess | 2013 |
Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Apolipoprotein | 2008 |
Alzheimer's Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Brain; Celecoxi | 2009 |
Long-term efficacy and safety of celecoxib in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cognition Disorders; De | 2007 |
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cogn | 2008 |
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cogn | 2008 |
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cogn | 2008 |
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cogn | 2008 |
5 other studies available for celecoxib and Cognition Disorders
| Article | Year |
|---|---|
[Cognitive-cytokine effect of nonsteroidal antiinflammatory drugs in the therapy of elderly patients with osteoarthritis].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cognition; Cognition Disorders; Cytokines; | 2017 |
A Cyclooxygenase-2 Inhibitor Reduces Vascular Wall Thickness and Ameliorates Cognitive Impairment in a Cerebral Small Vessel Diseases Rat Model.
Topics: Animals; Brain; Celecoxib; Cerebral Small Vessel Diseases; Cognition Disorders; Collagen Type I; Cyc | 2015 |
Celecoxib delays cognitive decline in an animal model of neurodegeneration.
Topics: Analysis of Variance; Animals; Celecoxib; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cytokine | 2012 |
Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat.
Topics: Aging; Animals; Celecoxib; Cognition Disorders; Corticosterone; Cyclooxygenase 2; Cyclooxygenase 2 I | 2002 |
Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Behavior, | 2006 |